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Various forms of hepatitis C virus (HCV)-related particles are produced from HCV-infected cells.
Measuring infectivity of a HCV sample with the conventional ‘foci counting method’ is laborious and
time-consuming. Moreover, the infectivity of a HCV sample does not correlate with the amount of viral
RNA that can be measured by real-time RT-PCR. Here we report a new assay suitable for quantifying
infectious HCV particles using aptamers against HCV E2, which is named ‘Enzyme Linked Apto-Sorbent
Assay (ELASA)’. The readout value of HCV ELASA linearly correlates with the infectious dose of an HCV
sample, but not with the amount of HCV RNA. We also demonstrated that the activities of anti-HCV
drugs can be monitored by HCV ELASA. Therefore, HCV ELASA is a quick-and-easy method to quantify
infectious units of HCV stocks and to monitor efﬁcacies of potential anti-HCV drugs.
& 2013 Elsevier Inc. All rights reserved.Introduction
Approximately 170 million people are estimated to be infected
by hepatitis C virus (HCV) worldwide (Hoofnagle, 2002). Chronic
infection of HCV often leads to liver cirrhosis and hepatocellular
carcinoma (Gottwein and Bukh, 2008; Memon and Memon, 2002).
No HCV vaccine is available to date, and the current standard
therapy, a combination of ribavirin and pegylated interferon-a
(peg-IFN-a), cures in only half of patients (Fried et al., 2002). Two
new direct-acting antiviral agents (DAA) targeting HCV NS3/4
protease, boceprevir and telaprevir, have become available very
recently, and more anti-HCV drugs are being developed (Vermehren
and Sarrazin, 2011).
HCV is a member of the Flaviviridae family, and the HCV
genome consists of a single-stranded positive sense RNA ofll rights reserved.
aboratory, POSTECH Biotech
y of Science and Technology,
-784, Republic of Korea.
.approximately 9.6 kb (Simmonds et al., 2005). The viral proteins
are translated as a polyprotein of about 3010 amino acids that is
processed co- and post-translationally by cellular and viral
proteases into structural (core, E1 and E2) and nonstructural
(p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) viral proteins (Reed
and Rice, 2000). The genomic RNA is encapsidated into core
proteins, and the nucleocapsid composed of the genomic RNA
and core proteins is budded into ER lumen while envelope
proteins E1 and E2 are loaded onto the virion particles
(Roingeard et al., 2004). Only a minor portion of virion particles
(1 out of 100–1000) produced in a model animal (Bukh, 2004) and
in a cell culture system (Lindenbach et al., 2005; Zhong et al.,
2005) are infectious. Core proteins exist in both infectious and
noninfectious HCV particles (Gastaminza et al., 2010,, 2006). In
contrast, HCV envelope proteins (E1 and E2) are known to be
associated with the infectious particles, not with the noninfec-
tious particles (Merz et al., 2011; Vieyres et al., 2010). The
envelope proteins have pivotal roles in HCV entry (Dubuisson
et al., 2008; Evans et al., 2007; Mazumdar et al., 2011; Pileri et al.,
1998; Ploss et al., 2009; Scarselli et al., 2002). The E2 proteins are
needed for attachment and entry of virions through interactions
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et al., 2007; Pileri et al., 1998; Ploss et al., 2009; Scarselli et al., 2002).
Therefore, the quantiﬁcation of HCV E2 in viral stocks could be a
logical approach to measure the infectious dose of a virus source. The
current state-of-the-art methods of measuring the amounts of HCV
are quantitative RT-PCR (Mellor et al., 1999) and immunological
measurement of core proteins (Tanaka et al., 2000). None of these
methods is suitable for measuring the infectious dose of HCV, but
these methods are for quantifying total virion particles including
both infectious and noninfectious ones.
Aptamers are oligonucleotides (DNA or RNA) that interact with
varieties of target molecules including proteins with high afﬁnity
and speciﬁcity (Ellington, 1994; Gold et al., 1995). Aptamers
have been employed in diverse applications based on molecular
recognition as analytical, diagnostic and therapeutic tools (Brody
and Gold, 2000; Famulok et al., 2007; Gold, 1995). Aptamers are
selected in vitro from an oligonucleotide library containing
random sequences by the method named ‘systematic evolution
of ligands by exponential enrichment (SELEX)’ (Ellington and
Szostak, 1990; Tuerk and Gold, 1990). Theoretically, a SELEXFig. 1. Generation of DNA aptamers against HCV envelope protein E2.
(A) Puriﬁcation of HCV E2 proteins from yeasts. 6 Histidine- and FLAG-tagged
E2 proteins were expressed in yeasts and then puriﬁed by afﬁnity chromatography
(Materials and methods). The puriﬁed E2 proteins were resolved by 12% SDS-PAGE
and visualized by Coomassie brilliant blue staining (left) or by Western blotting
with an anti-FLAG antibody (right). Numbers on the left side depict the apparent
molecular weights of protein size markers. The apparent molecular weight of
glycosylated recombinant E2 proteins was approximately 70 kDa. (B) The struc-
ture of modiﬁed uridine (Bz-dU) used in the advanced SELEX. The ‘R’ represents
benzylaminocarbonyl group (Bz).
Table 1
Binding afﬁnities (Kd values) and Bmax values of aptamers against HCV envelope prot
Pool Round 6 Round 8
Kd (nM) N/A 9.971.4 4.670.3
Bmax (%) 1972 6373 5671library with 40 nucleotide random sequence has 440 combina-
tional diversities. The SELEX process leads to enrichment of
oligonucleotides speciﬁcally interacting with a target molecule.
In order to increase binding afﬁnity of aptamers to target proteins,
we employed the ‘advanced SELEX technology’ using a modiﬁed
deoxyribonucleotide (Gold et al., 2010; Vaught et al., 2010).
Here we report a new assay system suitable for quantifying
infectious HCV particles using aptamers against HCV E2. In
principle, this system is similar to Enzyme-Linked Immuno-
Sorbent Assay (ELISA). The direct ELISA, which recognizes an
antigen, utilizes two different antibodies speciﬁc for the antigen
(Engvall and Perlmann, 1971). On the other hand, this new system
utilizes two different aptamers recognizing HCV E2. We named
this new system as ‘Enzyme Linked Apto-Sorbent Assay (ELASA)’
since this system is composed of two aptamers instead of
antibodies. Quantities of puriﬁed HCV E2 proteins of two major
genotypes [genotype 1 (1a and 1b) and genotype 2] were
measurable by the HCV ELASA system. Moreover, the HCV ELASA
was able to detect HCV particles containing envelope proteins of
either genotype 1 or 2 generated from in vitro cultivation systems.
To our surprise, the readout values of the HCV ELASA correlated
well with the infectious doses of HCV particles, but not with the
amounts of HCV RNAs in virus samples. We also showed that this
system is useful for monitoring effects of anti-viral drugs. There-
fore, the HCV ELASA is a quick-and-easy tool to quantify infec-
tious units of HCV stocks and to monitor efﬁcacies of potential
anti-HCV drugs using in vitro cultivation systems.Results
Generation of anti-HCV E2 aptamers with high afﬁnities via advanced
SELEX using a modiﬁed nucleoside.
In order to generate DNA aptamers against HCV E2, we
puriﬁed a truncated HCV E2 protein containing the luminal
domain (383–729 amino acids) of genotype 2a HCV (JFH) that
was expressed in yeasts (PBN204 strain). The yeast expression
system was used instead of an Escherichia coli system since post
translational modiﬁcation [glycosylation (Goffard and Dubuisson,
2003; Beeck et al., 2001) and disulﬁde bond formation (Dubuisson
and Rice, 1996; Fenouillet et al., 2008; Krey et al., 2010)] are
essential for proper folding and receptor binding of the polypep-
tide (Falkowska et al., 2007; Goffard et al., 2005; McCaffrey et al.,
2012; Slater-Handshy et al., 2004). Puriﬁcation of the recombi-
nant E2 protein was performed by afﬁnity chromatography based
on 6 Histidine and FLAG tags conjugated to the N-terminal and
C-terminal ends of the E2, respectively (Fig. 1A). Advanced SELEX,
using 5-benzylaminocarbonyl-dUridine (Bz-dU) instead of Thy-
midine, was performed to acquire aptamers with high afﬁnity and
speciﬁcity (Gold et al., 2010; Vaught et al., 2010) (Fig. 1B). After
8 rounds of selection, four aptamers (E2-A, -B, -C, -D) with high
afﬁnities to the puriﬁed E2 proteins were obtained (Table 1 and
Table S1), and the secondary structures of ssDNA aptamers were
predicted by using a web-based program Mfold (Supplementary
Fig. 1). The afﬁnities and Bmax values of aptamers ranged
Kd¼0.8–4 nM and 64–80%, respectively.ein E2 (genotype 2a JFH). N/A stands for ‘not available’.
E2-A E2-B E2-C E2-D
1.070.5 4.070.8 3.571.5 0.870.2
7576 7178 64711 8075
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apto-sorbent assay (ELASA)’ using aptamers against HCV E2 protein
To quantify HCV E2 proteins or HCV particles containing E2
proteins, we developed a new method named enzyme-linked
apto-sorbent assay (ELASA). Schematic diagram of the ELASA is
depicted in Fig. 2A. In principle, ELASA is similar to Enzyme-
Linked Immuno-sorbent Assay (ELISA) (Engvall and Perlmann,
1971). However, 2 aptamers recognizing 2 different regions of
HCV E2 were used in the HCV ELASA instead of 2 antibodies
recognizing a target molecule as in ELISA. In the ELASA system,
one of the aptamer pair (capture aptamer) is directly conjugated
onto the surface of a 96 well plate through NHS linkage, and the
other (detection aptamer) is biotinylated to snatch a streptavidin
conjugated with horse radish peroxidase (HRP) (Fig. 2A). In this
setting, the capture and detection aptamers bind to E2 proteins on
the virus surface, and the streptavidin-HRP speciﬁcally interacts
with the biotin-conjugated detection aptamer. In other words, the
HRP is indirectly connected to the well only when HCV E2
proteins or HCV particles with E2 exist in the well after the
washing step of ELASA. The amounts of HRP remaining in the well
are proportional to the amounts of HCV E2 or HCV particles
containing E2. The chemiluminescent signals from HRP are
measured at 450 nm. We tested all possible combinations of
aptamer pairs in exploring the best pair for ELASA (Fig. 2B). As a
source of HCV particles, we used HCV particles produced from an
in vitro HCV cultivation system based on a highly infectiousFig. 2. Development of an ELASA system. (A) Schematic diagram of ELASA. A pair of DNA
particle is depicted. The capture aptamer is immobilized on the plate through the ami
streptavidin conjugated with horse radish peroxidase (HRP) (left panel). The chemilum
different pairs of aptamers in ELASAs. HCV culture medium (100 ml, 1.00104 FFU/ml)
various capture aptamers (aptamers A–D) and then incubated at RT for 1 h. To detect t
treated in the wells at RT for 1 h, and then streptavidin–HRP conjugates were treated at
and lines represent the mean values and standard deviations from three independentvariant of JFH clone (Keum et al., 2012). Even though all four E2
aptamers have high afﬁnities to recombinant E2 proteins, only
aptamers B and D were functional for detecting HCV particles
(Fig. 2B). And the pair composed of capture aptamer B and
detection aptamer D showed the strongest detection signal
among the combinations of aptamer pairs (Fig. 2B). This capture
aptamer B and detection aptamer D pair was used for further
analyses of the ELASA system.
The sensitivity of the ELASA system was improved by using a
multivalent detection aptamer approach.
Avidity of probes can be increased by oligomerizing the probes
(Cuesta et al., 2010). Therefore, we tried to improve sensitivity of
the HCV ELASA system by oligomerizing the detection aptamer.
For this purpose, we used a biotinylated detection aptamer and
streptavidin, which forms a tetramer containing 4 biotin-binding
sites, conjugated with HRP (Fig. 3A). The multivalent detection
aptamers were generated by pre-incubating the streptavidin-
HRPs and the biotin-conjugated detection aptamers (Fig. 3B).
Several variants (mono-, di-, tri-, and tetramer) of streptavidin–
biotinylated aptamer complexes were observed when
streptavidin-HRPs and the biotin-conjugated detection aptamers
were incubated together. We performed ELASAs of HCV culture
media with either monovalent detection aptamers or multivalent
detection aptamers (Fig. 3C). The detection limit of the ELASA
system with the multivalent aptamers was 3.13–6.25102 FFU/ml,aptamers speciﬁcally interacting with different parts of E2 protein on a HCV virion
ne group, and the detection aptamer is conjugated with biotin that interacts with
inescent signals from HRP were measured at 450 nm (right panel). (B) Efﬁcacies of
was loaded on each well in an Immobilizer Amino 96 well plate conjugated with
he captured HCV particles, biotinylated detection aptamers (aptamers A–D) were
RT for 30 min (Materials and methods). No aptamer is a negative control. The bars
experiments.
Fig. 3. Improvement of sensitivity of ELASA using multivalent detection aptamers. (A) Schematic diagram of ELASA using multivalent detection aptamers. The multivalent
detecting aptamers were formed by pre-incubation of biotinylated detection aptamers and streptavidin that contains four biotin-binding sites. (B) Detection of
streptavidin-aptamer complexes. Streptavidin-HRP and biotin-conjugated detecting aptamers were incubated at RT for 2 h and then resolved on a 6% denaturing urea
polyacrylamide gel. The positions of aptamers were visualized by Sybro gold nucleic acid staining. The several forms (mono-, di-, tri-, and tetra-meric aptamer–streptavidin
complexes) were detected. (C) The sensitivities of ELASA using monovalent or multivalent aptamers. HCV samples were serially diluted from 3.13102 FFU/ml to 2.00104 FFU/ml
and ELASAs were performed. Chemiluminescent signals were measured at 450 nm. The ELASA values are depicted in logarithmic scale. The dots and lines represent the mean values
and standard deviations from three independent experiments.
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valent aptamers was 1.25–2.50103 FFU/ml (Fig. 3C). These
results indicated that the ELASA system using the multivalent
detection aptamers has about 4 fold higher sensitivity than
that using the monovalent detection aptamers. Therefore, the
further experiments were performed by the multivalent detection
aptamers.
The ELASA system detects puriﬁed HCV E2 proteins of various
genotypes
We investigated whether the HCV ELASA system can detect
and quantify the recombinant E2 protein of genotype 2a (JFH),
which was used in the SELEX of HCV E2 aptamers. Proteins were
serially diluted from 500 ng/ml to 4 ng/ml with SB18T0.05. The E2
proteins of genotype 2a were quantitatively detected with the
detection limit of approximately 16 ng/ml (Fig. 4A). Bovine serum
albumin (BSA), which was used as a negative control, showed a
basal level of signal even when tested at the highest concentra-
tion. Generally, aptamers recognize the tertiary structures of
target molecules in contrast to most antibodies recognizing linear
epitopes (Patel et al., 1997). Therefore, we investigated whether
the HCV ELASA system can detect E2 proteins of various geno-
types having diverse primary sequences since the tertiary struc-
tures of E2 proteins of various genotypes should share commonfeatures for receptor-binding (Pileri et al., 1998; Scarselli et al.,
2002), entry (Bartosch et al., 2003; Hadlock et al., 2000), and
assembly (Bianchi et al., 2011). The E2 of HCV genotype 1b (con1),
which is the most prevalent genotype in the world (Zeuzem,
2004), and that of genotype 1a (H77), which is widely distributed
in northern Europe and in the United States (Armstrong et al.,
2006; Esteban et al., 2008), were detected equally well by the HCV
ELASA system (Fig. 4C and B, respectively). These data suggested
that the ELASA is suitable for detecting and quantifying HCV E2
proteins of various genotypes.
The HCV ELASA system detects HCV particles of genotypes 1a and 2a
To explore whether the HCV ELASA system is suitable for
detecting virion particles of various genotypes, we investigated
whether the ELASA can detect HCV containing E2 proteins of
genotypes 1a and 2a. Viral stocks of genotypes 1a and 2a were
subjected to the HCV ELASA. As a source of HCV particles with
structural proteins of genotype 1a, we produced infectious
HCV that is a chimera encoding structural proteins of H77S and
nonstructural proteins of JFH (Yi et al., 2007,, 2006). Virion
particles of genotypes 1a and 2a were detected with detection
limits of about 3.8–7.8102 FFU/ml (Fig. 5B and A, respectively).
These results showed that the ELASA speciﬁcally detect the virus
associated E2 proteins. In conclusion, the above data suggested
Fig. 4. Detection of puriﬁed E2 proteins of various genotypes (1a, 1b and 2a) by
ELASA. The E2 proteins of various genotypes were puriﬁed by using a yeast
expression system. The puriﬁed E2 proteins of genotype 2a (A), 1a (B), and 1b
(C) were serially diluted from 4 ng/ml to 500 ng/ml with SB18T0.05 and detected
by ELASA. Bovine serum albumin (BSA) was used as a negative control. The
Chemiluminescent signals were measured at 450 nm. The ELASA values are depicted
in logarithmic scale. The dots and lines represent the mean values and standard
deviations from three independent experiments.
Fig. 5. Detection of HCV particles of genotype 2a and 1a by ELASA. HCV particles
containing E2 of genotype 2a (A) or 1a (B) were concentrated by centrifugation
and then re-suspended in SB18 (1:100 of the initial volume). HCV samples were
serially diluted with SB18T0.05 from 9.77101 FFU/ml to 1.00105 FFU/ml
for genotype 2a virus or from 1.88102 FFU/ml to 6.00103 FFU/ml for genotype
1a virus, and the amounts of HCV particles were measured by ELASAs. The
Chemiluminescent signals were measured at 450 nm. The ELASA values are
depicted in logarithmic scale. The dots and lines represent the mean values and
standard deviations from three independent experiments.
J.H. Park et al. / Virology 439 (2013) 13–22 17that the ELASA is suitable for detecting and quantifying HCV
particles of various genotypes.
Monitoring HCV proliferation by ELASA
Quantitative analyses of virus proliferation are essential for
monitoring the effects of medication of anti-viral drugs and for
identifying anti-viral drug candidates during drug development.
The quantiﬁcation of HCV RNA by real-time RT-PCR and the
titration of infectious virion particles are currently used for
monitoring proliferation of HCV. However, these methods are
laborious and time-consuming. Moreover, the amount of viralRNA and the infectious virus titer do not correlate well (Bukh,
2004; Lindenbach et al., 2005; Zhong et al., 2005). Recently, we
reported that the speciﬁc infectivity (deﬁned herein as focus-
forming unit per viral RNA molecule) of HCV changes during HCV
infection cycle (Keum et al., 2012). Therefore, a convenient assay
system suitable for measuring the infectious dose of a HCV
sample has been required in academic and medical ﬁelds.
We investigated whether the HCV ELASA is suitable for
monitoring anti-HCV effects of anti-HCV drugs. We observed
HCV proliferations using an in vitro HCV cultivation system
(Keum et al., 2012) with or without treatment of anti-HCV agents
interferon-alpha (IFN-a) and BMS-790052. IFN-a is currently used
for treatment of chronic HCV infection, and BMS-790052 is a
NS5A inhibitor in phase III clinical trials (Gao et al., 2010). The
anti-HCV agents were treated for 5 days from day 0 when HCV
was inoculated. The viral titers were measured by using the HCV
ELASA system with the samples taken every day from the Huh
7.5.1 cells culture media inoculated with HCV [0.3 multiplicity of
infection (MOI)]. The HCV titers increased gradually up to 5 days
post infection in the mock-treated virus culture. On the other
hand, viral titers remained at the basal level in the HCV culture
Fig. 6. Monitoring the effects of anti-viral drugs and characterization of virion
particles using HCV ELASA. (A) HCV was cultivated in the presence or absence of
antiviral drugs [BMS-790052 (1 nM) and interferon-a (500 IU/ml)] from the virus
inoculation time. The amounts of HCV particles were monitored by the HCV ELASA
until 5 days after infection. (B) The amounts of HCV particles were monitored by
the HCV ELASA from 3 days post infection to 8 days post infection. Anti-HCV drugs
were treated at 4 days after inoculation of HCV. (C) Comparison between ELASA
values and infectious HCV titers measured by foci counting method in the
fractions of a sucrose density gradient centrifugation. The ELASA values and the
virus titers are depicted in OD450 nm and FFU103/ml, respectively. The dots and
lines represent the mean values and standard deviations from three independent
experiments.
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viral titers, which were measured by foci formation, showed
similar patterns to the ELASA values (Table S2 A).
We also monitored the curing processes of HCV-infected cells
using the ELASA and the HCV cultivation system. Huh 7.5.1 cells
inoculated with HCV (0.3 MOI) were cultivated for 2 days (about
70% of cells were infected at this time point), splitted on 12 well
plates, and then cultivated for 2 more days. Infected cells were
treated with IFN-a or BMS-790052, and then the HCV titers in
the media were monitored by the ELASA. Precipitant decreases of
viral titers were observed from the culture media at 2 days after
the drug treatments (dotted lines in Fig. 6B). On the other hand,
viral titer was increased in the culture media of mock-treated
samples during this time (solid line in Fig. 6B). The viral titer in
the mock-treated cell culture media was decreased after 7 days
post infection due to the death of infected cells (Keum et al.,
2012). Changes of viral titers, which were measured by foci
formation, showed similar patterns to the ELASA values (Table
S2B). These data indicated that the ELASA system is suitable for
monitoring efﬁcacies of anti-HCV drug candidates and for ther-
apeutic follow-ups of anti-HCV drug treatments.
Density gradient analyses of viruses cultivated in vitro showed
that virion particles with densities of 1.10 to 1.14 g/ml have the
highest speciﬁc infectivity (Gastaminza et al., 2006; Grove et al.,
2008; Lindenbach et al., 2005). On the other hand, the majority of
viral RNAs was fractionated at buoyant densities between 1.15 g/ml
and 1.17 g/ml (Keum et al., 2012). This indicates that most of the
virus-related particles in the high density fractions are not
infectious. We measured viral titers with the HCV ELASA (solid
line in Fig. 6C) and with foci formation (dotted line in Fig. 6C). The
viral titers measured by the ELASA and foci formation were
peaked at buoyant density 1.11–1.14 g/ml as previous reported
(Gastaminza et al., 2006; Grove et al., 2008; Lindenbach et al.,
2005). These results indicated that the HCV ELASA can be used for
analysis of HCV infectivity since the ELASA values well-matched
with the viral infectivity values.
HCV infectivity correlates well with HCV ELASA value
HCV E2 has an essential role(s) in HCV infection of more than 95%
of infectious HCV particles since neutralizing antibodies targeting E2
reduced infectivity of viral stocks more than 95% (Brimacombe et al.,
2011). Therefore, it is plausible that the quantity of HCV E2 reﬂects
the infectivity of a HCV stock unlike the quantities of core and HCV
RNA that are known to exist in both infectious and noninfectious
particles (Merz et al., 2011; Vieyres et al., 2010). We investigated the
relationships among infectious viral dose, quantity of HCV RNA and
ELASA value in the culturemedia at the indicated times after infection
of HCV into Huh 7.5.1 cells (5 MOI). The infectious virus titers and the
amount of HCV RNA were measured by foci formation and real-time
RT-PCR, respectively. The ELASA values correlated well with the
infectious virus titers regardless of the collecting time (R2¼0.99)
(Fig. 7A). On the other hand, no correlation (R2¼0.40) was observed
between the ELASA values and the quantities of viral RNA (Fig. 7B). In
addition, no correlation (R2¼0.39) was observed between the virus
titers and the quantities of viral RNA (Fig. 7C). In conclusion, the
infectious virus titers strongly correlated with the ELASA values, and
the HCV ELASA is a quick, easy and reliable method to measure the
infectious dose of a HCV sample.Discussion
Measuring infectivity of HCV samples using a conventional
method (counting foci of HCV infected cells immunostained with
Fig. 7. Correlations among ELASA values, infectious HCV titer and the amount of HCV RNA. ((A)–(C)) Huh 7.5.1 cells were infected with HCV of genotype 2a (5 MOI), and
the culture media were collected every 24 h for 6 days. ELASAs of the HCV samples were performed as described in Materials and methods. The amounts of HCV RNAs and
infectious HCV titers were measured by quantitative RT-PCR and foci counting method, respectively. (Left panels) Infectious HCV titers and ELASA values (A), the amounts
of HCV RNAs and ELASA values (B), and the amounts of HCV RNAs and infectious HCV titers (C) in media collected in various days after infection are depicted in separate
graphs. (Right panels) Correlations between infectious HCV titers and ELASA values (A), the amounts of HCV RNAs and ELASA values (B), and the amounts of HCV RNAs and
infectious HCV titers (C) are depicted. The correlation coefﬁcient values (R2 values) and the best-ﬁtting lines by linear regression analyses are also depicted. The dots and
lines represent the mean values and standard deviations from three independent experiments.
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inoculated cells) takes long time (3–5 days), and the process is
laborious. Here we report a quick-and-easy method for measuring
the amount of infectious HCV. We developed an aptamer-based
assay system named as ELASA. The advanced SELEX technology
using BzdU instead of Thyamine, which was developed by Gold
et al. (2010), was applied to obtain aptamers with high afﬁnities.Four HCV E2-speciﬁc aptamers, which do not compete each other
for binding to E2, were obtained from the advanced SELEX. No
competition among the E2 aptamers indicates that the binding
sites of aptamers on HCV E2 do not overlap each other. Among the
different combinations of aptamer pairs, aptamers A and C did not
show positive signals in detecting HCV particles in ELASA (Fig. 2B)
even though these aptamers bind strongly to the puriﬁed HCV E2
J.H. Park et al. / Virology 439 (2013) 13–2220proteins (Table 1). On the other hand, the aptamer pair B and D
showed strong positive signals in the ELASA (Fig. 2B). An explana-
tion for the discrepancy between the functionality of aptamers A
and C in the ELASA system and the binding of the aptamers to
puriﬁed E2 protein is as follows: Aptamers B and D, but not A and
C, may bind to E2 proteins on HCV virion particles due to the
following reasons. (1) Aptamers B and D, but not A and C, may
bind to the native form of HCV E2 proteins on HCV particles. (2)
The binding sites for aptamers A and C on the E2 protein might be
shielded by other component(s) in virion particles such as the E1
protein that interacts with E2 (Beeck et al., 2000). (3) The binding
sites of aptamers A and C might reside very close to the trans-
membrane domain of HCV E2, which sterically hinders binding of
aptamers A and C to E2 proteins on virions. Related to this issue, it
is worth to note that aptamers B and D, but not A and C, inhibit
infection of HCV (data not shown). No effect of aptamers A and C
on HCV infection could be attributed to an inability of these
aptamers to bind to E2 proteins on HCV virions.
The HCV ELASA system using aptamers B and D could detect
E2 proteins of different genotypes of HCV including genotypes 1a,
1b and 2a (Fig. 4). This indicates that the HCV ELASA system is
useful for monitoring the infection of major genotypes of HCV
(genotypes 1 and 2). Moreover, the HCV ELASA may be able to
detect other genotypes of HCV such as genotypes 3–6 even
though we have not tested whether the ELASA can detect these
genotypes. The broad spectrum of the HCV ELASA in detecting
various genotypes suggests that the aptamers B and D recognize
the conserved regions in HCV E2 that are essential for infection of
the virus. Indeed we found that both aptamers B and D blocked
the infection of HCVcc into a Huh-7.5 cell (data not shown). On
the other hand, the aptamers A and C, which could not recognize
HCV virions, did not affect the HCVcc infection (data not shown).
Determination of the binding sites of aptamers B and D on HCV E2
remains to be investigated.
One interesting aspect of the HCV ELASA is that the ELASA value
correlates well with the infectious HCV titer of culture media but
not with the HCV RNA titer (Fig. 7). This indicates that the ELASA
system is a quick-and-easy method to measure the infectious virus
titer of HCV culture media. The ELASA values showed linearity from
3.91102 FFU/ml to 1.00105 FFU/ml (Fig. 5A). This indicates that
the quantiﬁcation of infectious virus titer is possible within this
range of infectious virus titer. The linear relationship between the
infectious HCV titer and the concentration of the E2 protein suggests
that the E2 protein has an important role(s) in infection of virion
particles. Several roles of HCV E2 during infection of virus have been
reported. E2 protein participates in the recognition of viral receptors
such as CD81 and SRB1 (Pileri et al., 1998; Scarselli et al., 2002).
Moreover, the E2-viral receptor interactions modulate host cell
functions to facilitate virus infection (Liu et al., 2012). However, it
is noteworthy that there exists a subpopulation of HCV virions that
is not detected by the ELASA (fraction 1.15 g/ml in Fig. 6C). The
infectious virion particles in this fraction 1.15 g/ml, which were not
detected by the HCV ELASA, could be the same viral entity that can
infect the neighboring cells in the presence of neutralizing E2
antibodies (Brimacombe et al., 2011). Further investigations are
required to conﬁrm this hypothesis.
Previously, an assay system for detection of HCV using
an aptamer against HCV E2 was reported (Chen et al., 2009).
Their system contained an antibody against HCV E2 (Li et al.,
2007) as a capture of HCV and an aptamer as a detector. In other
words, their system utilizes both an antibody and an aptamer. The
ELASA system, on the other hand, utilizes two aptamers recogniz-
ing distinct parts of HCV E2 as a capture and a detector,
respectively. Moreover, the previous report did not demonstrate
the relationship between the infectivity of the HCV and the
assay value.In summary, we developed a HCV ELASA that is suitable for
measuring infectious units in HCV stocks by using a pair of
aptamers against HCV E2. This ELASA is a quick-and-easy assay
system detecting both genotypes 1 and 2. Currently we are trying
to ﬁnd the right conditions for ELASA to quantify HCVs in HCV
patients’ sera.Materials and methods
Modiﬁed systematic evolution of ligands by exponential enrichment
(SELEX)
The advanced SELEX technology was used as described by Gold
et al. (2010). For positive selection of the 1st round, 50 pmol of
E2 protein was used in SELEX. For additional rounds of SELEX
(rounds 2–8), the amount of protein was reduced to 10 pmol.
Altogether, 8 rounds of SELEX were performed to enrich target-
speciﬁc oligonucleotides.
Cloning and sequencing of selected aptamers
After 8 rounds of SELEX, aptamers were ampliﬁed by QPCR
using 50- and 30-primers, and then cloned into TA cloning Kit
(Solgent, Korea). Fifty colonies were picked for each sample and
the cloned parts were sequenced by Solgent. Sequences were
aligned using the ‘aptamer motif searcher’, an in-house program
of Aptamer Sciences (Inc.), and a pattern analysis was performed.
Enzyme linked apto-sorbent assay (ELASA)
A pair of aptamers was used in developing an ELASA system.
NH2-aptamers (100 nm) were conjugated on the bottom of an
Immobilizer
TM
Amino 96-well plate (Thermo scientiﬁc) by incu-
bating in coupling buffer [100 mM sodium phosphate (pH 7.0),
120 mM NaCl, 5 mM KCl, and 5 mM MgCl2] for 2 h at room
temperature (RT). After washing the wells three times with
phosphate-buffered saline (PBS) with 0.05% (w/v) Tween-20
(PBST), 100 ml of recombinant protein solutions or virus samples
(HCVcc) in SB18T0.05 [40 mM HEPES (pH 7.5), 120 mM NaCl,
5 mM KCl, 5 mM MgCl2 and 0.05% Tween-20] were added to each
well and incubated for 1 h at RT. The wells were washed three
times, and the mixture (100 ml) of the biotin-conjugated aptamer
(10 nM) and streptavidin-conjugated HRP (0.5 ml, R&D System),
which was pre-incubated for 2 h at RT, was added and then
further incubated for 1 h at RT. The wells were washed three
times. Finally, the samples were incubated with 100 ml of TMB
solution (Invitrogen), and the chemiluminescent signals from HRP
were measured at 450 nm.
Protein expression and puriﬁcation
For constructions of plasmids expressing the luminal domains
of E2 of genotypes HCV 1a, 1b and 2a, the nucleotides 1150–2175
of H77 (genotype 1a), nucleotides 1150–2175 of con1 (genotype
1b), and nucleotides 1150–2187 of JFH1 (genotype 2a) were
ampliﬁed by PCR with 1a primer pair (50-GAAACCCACGT-
CACCGGGGG-30 and 50-CAGAAGGAACAGGAGAACG-30), 1b primer
pair (50-GGAACCTATGTGACAGGGGG-30 and 50-AAGAAGGAAGAG-
CAACAGGA-30), and 2a primer pair (50-GGCACCACCACCGTTG-
GAGG-30 and 50-GAGCAGGAATAAGAGTACCA-30), respectively.
The PCR products were treated with Nhe1/Hind3 and cloned into
the corresponding sites of plasmid p425-GPD containing 6 Histi-
dine coding region and a FLAG tag. E2 proteins were expressed in
yeasts (strain PBN204) after transforming the cells with plasmid
p425-GPD-E2. Yeasts were harvested at 1 OD600 and resuspended
J.H. Park et al. / Virology 439 (2013) 13–22 21in lysis buffer [20 mM sodium phosphate (pH 7.5), 300 mM NaCl,
1 mM PMSF and 1% (w/v) Triton -100]. E2-His-FLAG proteins
were allowed to bind to talon metal afﬁnity resin (Clontech
Laboratories) for 2 h at 4 1C, and the resin-bound proteins were
eluted by 200 mM Imidazole in lysis buffer. The eluted proteins
were allowed to bind to ANTI-FLAG M2 afﬁnity gel (Sigma
Aldrich) in lysis buffer for 2 h at 4 1C and eluted by 100 ug/ml
3 FLAG peptide (Sigma Aldrich) in lysis buffer. The proteins
were dialyzed in PBS.
Production of infectious HCV
RNAs for production of HCVcc were synthesized by in vitro
transcription using T7 RNA polymerase (Stratagene). The plas-
mids pJFH-m4 (Kim et al., 2007) and pH-(NS2)-J (Yi et al., 2006,
2007) were linearized with XbaI and then used as templates for
transcription. The plasmid Jc1 E2 FLAG containing an infectious
HCV sequence with a FLAG epitope in the E2 gene was linearized
with Mlu1 (Merz et al., 2011) and then used as a template
for transcription. Huh7.5.1 cells were transfected with RNAs as
previously described (Zhong et al., 2005). At 3–5 days after
transfection, the culture media containing viruses were collected,
ﬁltered through a 0.45 mm ﬁlter, and inoculated onto naı¨ve Huh
7.5.1 cells for 5 h at 37 1C. The cells were cultivated for 48–72 h
prior to the analyses of HCV infection. The infectious titers (focus
forming units [FFU]/ml) of HCVcc were determined as described
previously (Zhong et al., 2005).
RNA puriﬁcation and real-time RT-PCR
Viral RNAs were isolated from clariﬁed cell supernatants by
trizol/chloroform extraction method using a TRI reagent (Invitro-
gen). Total RNAs were reverse transcribed using Improm II
reverse transcriptase (Promega), and the cDNAs were subjected
to real-time PCR analyses for quantiﬁcation using Sybr premix
Ex Taq (Takara). Primer sequences for reverse transcription-PCR
and real-time PCR were 50-GTCTAGCCATGGCGTTAGTA-30 and
50-CTCCCGGGGCACTCGCAAGC-30, respectively.
Sucrose gradient density centrifugation
The HCV-infected cell culture medium was centrifuged at
4000 rpm for 7 min at 4 1C to remove cellular debris, and the
supernatant was loaded on a 20% sucrose cushion and centrifuged
in a 45Ti rotor (Beckman Coulter) at 36,000 rpm for 4 h at 4 1C.
The pellets were resuspended in TNC buffer [10 mM Tris–HCl (pH
7.4), 150 mM NaCl, and 1 mM CaCl2] and applied onto a 20–60%
sucrose gradient (10.5 ml volume) in a SW41 tube (Beckman
Coulter) and centrifuged at 40,000 rpm for 16 h at 4 1C. A total of
10 fractions (1 ml each) were collected from the top to bottom of
the sucrose gradient. The sucrose in each fraction was diluted
with PBS to a 1:12 ratio, and then the samples were centrifuged
at 40,000 rpm for 16 h at 4 1C in a Beckman SW41 rotor. The
resulting HCV pellets were dissolved in PBS and aliquoted for
subsequent studies.Acknowledgments
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